3db8 › Citations

Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors.

Hanan EJ, Fucini RV, Romanowski MJ, Elling RA, Lew W, Purkey HE, VanderPorten EC, Yang W
Bioorg Med Chem Lett 18 5186-9 (2008)
Cited: 7 times
EuropePMC logo PMID: 18790636

Abstract

A series of 2-amino-isoxazolopyridines was designed and synthesized as Polo-like kinase (Plk) inhibitors. Key SAR and crystallographic data are discussed. More advanced analogues inhibit Plk1 with good enzymatic activity and modest cell-based activity. Differential selectivity among the three Plk isoforms is observed.

Reviews citing this publication (2)

  1. Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity. Murugan RN, Park JE, Kim EH, Shin SY, Cheong C, Lee KS, Bang JK. Mol Cells 32 209-220 (2011)
  2. PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis. Kumar S, Kim J. Biomed Res Int 2015 705745 (2015)

Articles citing this publication (5)

  1. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T. Chembiochem 10 1145-1148 (2009)
  2. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors. Sato Y, Onozaki Y, Sugimoto T, Kurihara H, Kamijo K, Kadowaki C, Tsujino T, Watanabe A, Otsuki S, Mitsuya M, Iida M, Haze K, Machida T, Nakatsuru Y, Komatani H, Kotani H, Iwasawa Y. Bioorg Med Chem Lett 19 4673-4678 (2009)
  3. Preparation of orthogonally protected (2S, 3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) as a phosphatase-stable phosphothreonine mimetic and its use in the synthesis of Polo-box domain-binding peptides. Liu F, Park JE, Lee KS, Burke TR. Tetrahedron 65 9673-9679 (2009)
  4. Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors. Sun J, Lv PC, Guo FJ, Wang XY, Xiao-Han, Zhang Y, Sheng GH, Qian SS, Zhu HL. Eur J Med Chem 81 420-426 (2014)
  5. Targeting Adaptive IRE1α Signaling and PLK2 in Multiple Myeloma: Possible Anti-Tumor Mechanisms of KIRA8 and Nilotinib. Yamashita Y, Morita S, Hosoi H, Kobata H, Kishimoto S, Ishibashi T, Mishima H, Kinoshita A, Backes BJ, Yoshiura KI, Papa FR, Sonoki T, Tamura S. Int J Mol Sci 21 E6314 (2020)


Quick links